This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The analysis was based on an RCT. The authors only reported limited information for this field, referring instead to the clinical paper (McCarthy et al. 2004 ).
Analysis of effectiveness
It was not reported whether the analysis was conducted on an intention to treat basis or on treatment completers only. In addition, details on the comparability of the two patient groups were not reported in the current study. The reader is referred to the separate clinical paper for further details (McCarthy et al. 2004) . The authors used the QALY as the primary outcome based on the EQ5D instrument. EQ5D measures patient Quality of Life across 5 dimensions, namely: mobility, self care, usual activities, pain/discomfort and anxiety/depression. The patients' health states were evaluated using the EuroQol 5D (EQ 5D) questionnaires through face to face interviews at baseline, and the 1 , 6 and 12 month follow-up after initiation of the programmes.
Effectiveness results
In the home-based group, the mean EQ-5D score was 0.50 (standard error, SE=0.03) at baseline, 0.52 (SE=0.03) at 1 month, 0.54 (SE=0.03) at 6 months and 0.53 (SE=0.03) at 12 months. The mean change in EQ-5D scores over the 12-month period was 0.022 (SE=0.03).
In the class-based group, the mean EQ-5D score was 0.54 (SE=0.03) at baseline, 0.60 (SE=0.02) at 1 month, 0.58 (SE=0.02) at 6 months and 0.58 (SE=0.02) at 12 months. The mean change in EQ-5D scores over the 12-month period was 0.045 (SE=0.03)
Clinical conclusions
The analysis demonstrated that the combination of a supplementary class-based exercise programme with a home-based programme achieved somewhat better EQ-5D scores over the trial period in comparison with the home-based programme alone, but the difference was not statistically significant. The combined programme had a bigger impact on the patients' health states in the first month after initiation of the intervention.
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). EQ-5D scores were obtained through faceto-face interviews at baseline, and 1, 6 and 12 months after the initiation of treatment. Then, EQ-5D scores were converted into utility scores based on a "tariff" retrieved from interviews conducted with 3,395 citizens in the UK.
Direct costs
From the NHS perspective, the direct costs included in the analysis were for GP home visit, GP surgery visit, district nurse visit, practice nurse visit, day hospital attendance, day case attendance, inpatient hospitalisation, outpatient attendances, and accident and emergency attendances. Resource use was based on actual data derived from the patients' medical records and patient questionnaires conducted at baseline, and 1, 6 and 12 months after the initiation of treatment. The costs and the quantities were reported separately. Overheads, capital costs and training costs were included in the analysis, accounting for a class of average size and duration. All costs were derived from published sources and were appropriately adjusted for inflation. Discounting was not relevant as the costs were incurred within a period of 12 months. The price year was reported (1999/2000) .
Statistical analysis of costs
Based on the assumption that data were missing at random, the authors imputed missing data using SOLAS software (Statistical Solutions Ltd.) using a non-parametric approach (i.e. the propensity score method). Carrying out multiple imputations, multiple data series were created, each with different imputed values for missing values. Values were assigned to each of the five dimensions of the EQ-5D and for each missing component of the resources used. whether the study sample was representative of the study population because no details of the patients were provided. It is not possible to comment on the internal validity of the effectiveness study since the authors referred to a separate paper for details of the clinical study. In addition, no power calculations were reported. Thus, it was not possible to ascertain whether the results obtained were due to the intervention or to chance.
Validity of estimate of measure of benefit
The measure of benefits used was health utility (QALYs), measured over 12 months using the EQ-5D questionnaire.
Validity of estimate of costs
The analysis of the costs was performed from the perspective of the NHS. As such, it appears that all the relevant categories of costs have been included in the analysis. The costs and the quantities were reported separately, thus enhancing the reproducibility of the study in other settings. Appropriate statistical and sensitivity analyses were performed to assess the robustness of the results. The costs were appropriately inflated and the price year was reported, thereby enhancing any future reflation exercises. Discounting was appropriately not carried out.
